Ravinder Dhawan

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Cost-effectiveness of gene-expression profiling for tumor-site origin
    John Hornberger
    Cedar Associates LLC, Menlo Park, CA 94025, USA
    Value Health 16:46-56. 2013
  2. doi request reprint A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs
    John Hornberger
    Stanford University School of Medicine, Stanford, CA, USA
    Value Health 15:1014-21. 2012
  3. doi request reprint Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis
    John Hornberger
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Kidney Dis 60:280-7. 2012
  4. doi request reprint Laboratory-developed test--SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks
    John Hornberger
    Cedar Associates LLC, Menlo Park, California 94025, USA
    Genet Test Mol Biomarkers 16:605-14. 2012
  5. doi request reprint Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review
    John Hornberger
    Stanford University School of Medicine, Stanford, CA, USA
    J Natl Cancer Inst 104:1068-79. 2012
  6. ncbi request reprint Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
    John Hornberger
    The SPHERE Institute Acumen, Burlingame, California 94010, USA
    AIDS Res Hum Retroviruses 22:240-7. 2006
  7. doi request reprint The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
    John Hornberger
    Cedar Associates LLC, Menlo Park, CA, USA
    Eur J Haematol 85:484-91. 2010

Collaborators

Detail Information

Publications7

  1. doi request reprint Cost-effectiveness of gene-expression profiling for tumor-site origin
    John Hornberger
    Cedar Associates LLC, Menlo Park, CA 94025, USA
    Value Health 16:46-56. 2013
    ..A cost-effectiveness analysis of GEP TOO testing versus usual care was conducted from a US third-party payer perspective...
  2. doi request reprint A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs
    John Hornberger
    Stanford University School of Medicine, Stanford, CA, USA
    Value Health 15:1014-21. 2012
    ....
  3. doi request reprint Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis
    John Hornberger
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Kidney Dis 60:280-7. 2012
    ..We assessed the economic implications for modality choice of the revised Medicare payment system...
  4. doi request reprint Laboratory-developed test--SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks
    John Hornberger
    Cedar Associates LLC, Menlo Park, California 94025, USA
    Genet Test Mol Biomarkers 16:605-14. 2012
    ..Our goal with the LDT-SynFRAME system is to promote a well-informed dialog among all the stakeholders responsible for the development, approval, reimbursement, and use of new molecular classifiers...
  5. doi request reprint Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review
    John Hornberger
    Stanford University School of Medicine, Stanford, CA, USA
    J Natl Cancer Inst 104:1068-79. 2012
    ..We performed a systematic review of the literature on clinical validity/utility, change in clinical practice, and economic implications of ESBC stratifiers...
  6. ncbi request reprint Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
    John Hornberger
    The SPHERE Institute Acumen, Burlingame, California 94010, USA
    AIDS Res Hum Retroviruses 22:240-7. 2006
    ..5 years among treatment-experienced HIV-infected patients. The cost-effectiveness of ENF is comparable to many existing treatment and prevention management strategies for HIV...
  7. doi request reprint The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
    John Hornberger
    Cedar Associates LLC, Menlo Park, CA, USA
    Eur J Haematol 85:484-91. 2010
    ..To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden...